Compare Biogen Inc (BIIB) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs PulteGroup, Inc. — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while PulteGroup, Inc. trades at $129.92 (market cap $25.22B). The key difference: Biogen Inc is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.79% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PHM | |
|---|---|---|
Market Cap | $30.13B | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $142.56 |
52-Week Low | $128.93 | $110.11 |
Enterprise Value | $37.20B | $25.64B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
PulteGroup (PHM) trades at $129.35, down 0.54% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $2.48, beating estimates, but revenue and margins face pressure. Analyst consensus is a Moderate Buy with a $137.20 price target, and recent news highlights operational expansion into Northwest Florida and workplace recognition.
The outlook remains cautiously optimistic supported by a solid balance sheet and community growth, though margin compression and housing market affordability challenges present near-term risks. The stock offers value with a P/E of 13.53, but investors should monitor earnings consistency and industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
